The cobas^® HPV Test: 3 hrHPV results in one test for confident risk stratification¹

The detail to make decisions based upon your patient’s real risk

Trust cobas^®HPV Test, a clinically validated FDA-approved and CE-marked assay that identifies high-risk HPV with simultaneous individual genotyping of the most oncogenic HPV16 and HPV18.

The cobas^® HPV Test has the potential to set a new standard of testing:

Significantly enhances risk stratification
Lets you focus on the few women who need aggressive treatment
Lets you reassure the vast majority of women that they are at very low risk

Confidence with the cobas^® HPV Test

Precise results you can trust

The cobas^® HPV Test offers:

No cross-reactivity with low-risk HPV types
Results are positive, negative, or invalid with no gray zone
Reproducible results with real-time PCR

Reduced false negatives¹

ß-globin internal control for sample adequacy

Reduced false positives¹

External control
No cross-reactivity with low-risk HPV genotypes

For additional technical specifications on the cobas^® HPV Test, visit molecular.roche.com

The detail to make decisions based upon your patient’s real risk

Confidence with the cobas^® HPV Test

Precise results you can trust

Roche Molecular Systems

HPV Resources

The detail to make decisions based upon your patient’s real risk

Confidence with the cobas® HPV Test

Precise results you can trust

Roche Molecular Systems

HPV Resources

Confidence with the cobas^® HPV Test